Cargando…

Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Aberrant Wnt signaling has been associated with many types of cancer. However, the association of inherited Wnt pathway variants with clinical outcomes in prostate cancer patients receiving androgen deprivation therapy (ADT) has not been determined. Here, we comprehensively studied the contribution...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geng, Jiun-Hung, Lin, Victor C., Yu, Chia-Cheng, Huang, Chao-Yuan, Yin, Hsin-Ling, Chang, Ta-Yuan, Lu, Te-Ling, Huang, Shu-Pin, Bao, Bo-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5187770/ https://www.ncbi.nlm.nih.gov/pubmed/27898031 http://dx.doi.org/10.3390/ijms17121970

Ejemplares similares

NRG1 Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
por: Huang, Shu-Pin, et al.
Publicado: (2021)

Genetic Variants in CASP3, BMP5, and IRS2 Genes May Influence Survival in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
por: Huang, Shu-Pin, et al.
Publicado: (2012)

Molecular Markers in Sex Hormone Pathway Genes Associated with the Efficacy of Androgen-Deprivation Therapy for Prostate Cancer
por: Yu, Chia-Cheng, et al.
Publicado: (2013)

Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy
por: Lin, Yen-Chi, et al.
Publicado: (2021)

Patients receiving androgen deprivation therapy for prostate cancer have an increased risk of depressive disorder
por: Chung, Shiu-Dong, et al.
Publicado: (2017)

Decreased Risk of Renal Calculi in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
por: Lin, Chien-Yu, et al.
Publicado: (2020)

Genetic variants of the autophagy pathway as prognostic indicators for prostate cancer
por: Huang, Chao-Yuan, et al.
Publicado: (2015)

Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival
por: Bao, Bo-Ying, et al.
Publicado: (2016)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2019)

TNFRSF13B is a potential contributor to prostate cancer
por: Li, Chia-Yang, et al.
Publicado: (2022)

A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer
por: Huang, Eric Y., et al.
Publicado: (2018)

Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy
por: Lorenzo, Giuseppe Di, et al.
Publicado: (2022)

No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study
por: Kao, Li-Ting, et al.
Publicado: (2017)

Vitamin D receptor-binding site variants affect prostate cancer progression
por: Lin, Victor C., et al.
Publicado: (2017)

Androgen Deprivation Therapy and Cardiovascular Risk in Chinese Patients with Nonmetastatic Carcinoma of Prostate
por: Huang, Gang, et al.
Publicado: (2014)

Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma
por: Lee, Chi-Ho, et al.
Publicado: (2017)

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy
por: Lee, C Ellen, et al.
Publicado: (2012)

Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Shore, Richard, et al.
Publicado: (2021)

Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer
por: Lu, Yu-Cheng, et al.
Publicado: (2022)

Prognostic Relevance of Methylenetetrahydrofolate Reductase Polymorphisms for Prostate Cancer
por: Lin, Victor C., et al.
Publicado: (2016)

Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy
por: Wang, Yanqing, et al.
Publicado: (2016)

Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation
por: Hou, Wei-Hsien, et al.
Publicado: (2017)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders
por: Liu, Jui-Ming, et al.
Publicado: (2020)

The Response of Prostate Cancer to Androgen Deprivation and Irradiation Due to Immune Modulation
por: Wu, Chun-Te, et al.
Publicado: (2018)

Subsequent risk of acute urinary retention and androgen deprivation therapy in patients with prostate cancer: A population-based retrospective cohort study
por: Yang, Teng-Kai, et al.
Publicado: (2020)

Medication utilization evaluation of androgen deprivation therapy for prostate cancer in Taiwan
por: Liao, Kuang-Ming, et al.
Publicado: (2020)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
por: Liu, Jui-Ming, et al.
Publicado: (2021)

Cancer Stem Cell Gene Variants Predict Disease Recurrence in Patients Treated with Radical Prostatectomy for Prostate Cancer
por: Lin, Victor C., et al.
Publicado: (2017)

Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer
por: Chang, Hao-Han, et al.
Publicado: (2022)

Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis
por: Yunfeng, Gao, et al.
Publicado: (2017)

Predictive Clinical Indicators of Biochemical Progression in Advanced Prostate Cancer Patients Receiving Leuplin Depot as Androgen Deprivation Therapy
por: Chen, Chien-Hua, et al.
Publicado: (2014)

Genetic variants in the circadian rhythm pathway as indicators of prostate cancer progression
por: Yu, Chia-Cheng, et al.
Publicado: (2019)

Prostate-selective α antagonists increase fracture risk in prostate cancer patients with and without a history of androgen deprivation therapy: a nationwide population-based study
por: Kao, Wei-Heng, et al.
Publicado: (2018)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer
por: Lee, Chung-Lin, et al.
Publicado: (2022)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Associations between Peripheral Thromboembolic Vascular Disease and Androgen Deprivation Therapy in Asian Prostate Cancer Patients
por: Lu, Yu-Chuan, et al.
Publicado: (2019)

Androgen Deprivation Therapy for Prostate Cancer Did Not Increase the Risk of Retinal Vascular Occlusion: A Population-Based Cohort Study
por: Lin, Hsin-Le, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qbcgum3alklgdeecidhf3j465e